Reporter Yan Guowen and Cao Xueping report from Beijing

On October 25, BeiGene (688235. SH) said in a statement on its WeChat official account: "Recently, BeiGene learned that an employee of the company is cooperating with the investigation. Based on what is currently known, the employee's involvement in the incident is not related to BeiGene. ”

BeiGene says it will continue to value and follow the principles of operating that are legal, compliant, and have high ethical standards.

According to the Economic Observer, Yin Min was taken away by the Shenzhen anti-smuggling department to cooperate with the investigation.

According to BeiGene's official website, Min Yin officially joined BeiGene in January 2022 as Chief Commercial Officer for Greater China.

From 2006 to 2021, Min Yin worked at AstraZeneca, during which time she served as Chief Financial Officer, Head of Strategic Projects in Europe, Compliance Officer in Greater China, Vice President of Commercial and Channels, General Manager of Hong Kong and Macau, and General Manager of China Oncology Division.

Previously, Bloomberg reported that five current and former employees of AstraZeneca were detained by Shenzhen police earlier this summer. Bloomberg, citing people familiar with the matter, said one of the investigations related to the company's collection of patient data, which may have violated data privacy laws, and that some of the people were also suspected of importing Tremelimumab, a CTLA-4 antibody that was not approved at the time. In a statement in response to Bloomberg's inquiry, AstraZeneca said: "We are aware that a small number of our employees in China are under investigation and have no further information to share at this time." ”

On October 18, 2024, according to the information on the official website of CDE, AstraZeneca submitted a marketing application for the CTLA-4 antibody drug Tremelimumab injection, which has previously been approved for marketing overseas in combination with PD-L1 antibody for the first-line treatment of hepatocellular carcinoma.

Yin Min has worked at AstraZeneca for 15 years, and the oncology division he is responsible for was exposed by the National Health Insurance Administration in early 2022 for suspected fraud of medical insurance funds.

On January 29, 2022, the National Health Insurance Administration notified AstraZeneca staff of the suspected fraud of the medical insurance fund. According to the report, in response to the fact that AstraZeneca staff was suspected of tampering with the genetic test results of tumor patients to defraud the medical insurance fund, the person in charge of the Fund Supervision Department of the National Health Insurance Bureau said that according to the clues reported by the masses in the early stage, the National Health Insurance Bureau urged Shenzhen to set up a joint task force composed of medical insurance, public security, health, market supervision and other departments to conduct an in-depth investigation of the case, and all the suspects have been arrested.

(Editor: Cao Xueping Review: Tong Haihua Proofreader: Yan Yuxia).